Headache Response Rate1*

Lipton study design: Phase III, prospective, randomized, double-blind, parallel-group, single-dose, placebo-controlled, multicenter, safety and efficacy study assessing the efficacy of diclofenac potassium 50 mg (n=343) for oral solution vs placebo (n=347) for the treatment of migraine pain.

DSK_LowMigraineRecur

Lipton Study1

Approximately 65% of patients taking CAMBIA were pain-free or had only mild pain at 2 hours (vs 42% with placebo).1

*Headache response is defined as reduction of moderate or severe pain to mild or no pain at 2 hours.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (CONTINUED)
Exacerbation of Asthma Related to Aspirin Sensitivity 

CAMBIA is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).

Serious Skin Reactions
NSAIDs, including diclofenac, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events can occur without warning.

CAMBIA should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. CAMBIA is contraindicated in patients with previous serious skin reactions to NSAIDs.

Reference

1. Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010;30(11):1336-1345.